4d Molecular Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
4D Molecular Therapeutics reports increased Q3 2025 net losses amid strategic pipeline prioritization, significant capital raises, and positive clinical trial progress for 4D-150 and 4D-710.
NASDAQ
4D Molecular Therapeutics reports accelerated Phase 3 timelines for its lead wet AMD gene therapy, 4D-150, alongside positive DME data and a strategic workforce reduction to extend cash runway.
NASDAQ
4D Molecular Therapeutics focuses on advancing 4D-150 and 4D-710, seeking strategic alternatives for other clinical programs, and reports a net loss of $48.0 million for Q1 2025.
NASDAQ
10-Q: 4D Molecular Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
4D Molecular Therapeutics reports a net loss of $43.8 million for the third quarter of 2024, with increased research and development expenses and a decrease in collaboration revenue compared to the same period in 2023.
NASDAQ
10-Q: 4D Molecular Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
4D Molecular Therapeutics reports a net loss of $34.95 million for the second quarter of 2024, alongside updates on clinical trials and financial activities.
NASDAQ
10-Q: 4D Molecular Therapeutics Reports First Quarter 2024 Financial Results, Bolstered by Public Offering
4D Molecular Therapeutics reports a net loss of $32.4 million for the first quarter of 2024, while significantly increasing cash reserves through a public offering.